European Proficiency Study with Control Serum for the Tumor Marker CA 19-9 Measured on Different Test Systems. Clin. Lab. 59 (2013) 185-192.
Manufacturer of Custom-Designed Controls
Literature
Alpha-1-Fetoprotein (AFP): International Proficiency Study with Different Test Systems.
Clin. Lab. 57 (2011) 669 – 675.
Reinsberg, J., Bätz, O., Bertsch, T., Bewarder, N., Deschner, W., Drescher, V., Dronsek, M., Emami, M., Keller, R., Klemm, M., Koch, H.-U., Meissner, J., Plecko, T., Schauer, I., Schweiger, A.M., Ullrich, A., Van De Loo, H.-M., Zwirner, M.
Precision and long-term stability of different Estradiol immunoassays assessed in a multi-center quality control study.
Clin. Lab. 55 (2009) 201-206.
Demir, A.Y., Bonfrer, J.M.G., Lentjes, E.G.W.M.
Harmonisation of CEA, CA 125, CA 15-3 and CA 19-9 assay results: A pilot study within the framework of the Dutch project "Calibration 2000".
Ned. Tijdschr. Klin. Chem. Labgeneesk 32 (2007) 252-254.
Bewarder, N.
CA 15-3-testing in the past and today: Comparison of two proficiency studies.
Labquality News 12 (2007) 29-31.
Bewarder, N., Abmeier, F., Bergmann, S., Drohla, S., Drescher, V., Gerstmayer, A., Kuß, S., Melamies, L., Miksch, R., Ortin, V., Rietschel-Klein, A., Neumeister, V., Odarjuk, J., Stratmann, M.M., Weinhold, A., Wiesner, B., Wildbredt, D.A., Wollenberg, P., Zinsmeyer, J., Zogbaum, M., Zwerenz, P., Zwirner, M., Wood, W.G.
Multicentre Evaluation of Performance of C-Reactive Protein Analysis over a One-Year Period.
Clin. Lab. 52 (2006) 639-654.
Hubl, W., Demant, T., Albrecht, S., Bewarder, N., Grunow, G., Keller, R., Klapdor, R., Klos, K.-J., Kruse, K., Müller, R., Päge, I., Schmidt, R., Stolle, H., Wiefelspütz, J., Vom Baur, E., Zinsmeyer, J., Zwirner, M.
A multi-center quality control study of different CA 15-3 immunoassays.
Clin. Lab. 51 (2005): 641-645.
Zwirner, M.
Demands on reference materials for optimized quality control in tumor marker diagnosis.
Labquality News 10 (2005) 40-44.
Bewarder, N., Müller, P.
External quality control program for the inter-laboratory quality control.
Anticancer Res. 20 (2000) 5213-5216.
Renard, C., Cheminel, V., Prevosto, J. M., Soares, O., Chaulet, J.-F.: Cobas Core II
Evaluation of analytical performance and integration in the endocrine and tumor marker laboratory.
Clin. Lab. 43 (1997) 843-855.
Kötting, J., Heinemann, G., Salb, I., Maier-Lenz, H.
Evaluation of the Cobas Core II immunochemistry analyser.
J. Autom. Chem. 18 (1996) 205-215
Fiedler, H., Kessler, A.-C., Köhler, P.
Results of a multicentre study on the analytical reliability of the tumour markers CEA, CA 15-3, CA 19-9, CA 72-4 and CA 125.
Klin. Lab. 40 (1994) 873-880.
Zwirner, M., Risse, T., Benz, R., Birkmeyer, G. D., Buchterkirche, W., Baum, U., Brandt, B., van Dalen, A., Förster, R., Hubl, W., Kapp, S., Klapdor, R., Spitz, J., Wieser, N.
Determination of CA 19-9 with various commercial assays. Results of an international proficiency study. In: R. Klapdor (ed): Current tumor diagnosis: Applications, clinical relevance, research, trends.
W. Zuckschwerdt Verlag, München (1994) 481-486.
Zwirner, M.
Longitudinal quality control of tumor markers assays. Results of an international proficiency study with CEA. In: R. Klapdor (ed): Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.
W. Zuckschwerdt Verlag, München (1992) 283-290.
Zwirner, M., Bieglmayer, C., de Bruijn, H. W., Crombach, G., Ebert, G., Kreienberg, R., Kißing, F., Klietmann, W., Schmid, L., Schindler, A. E., Sturm, G., Wieser, N., Wiebecke, K., Würz, H.
Results of an international proficiency study with the SCC tumor marker. In: R. Klapdor (ed): Recent results in tumor diagnosis and therapy.
W. Zuckschwerdt Verlag, München (1990) 285-289.
Birkmayer, G. J. D., Schwartz, M. K., Klavins, J. V.
Quality assurance of tumor marker assays.
J. Tumor Marker Oncol. 5 (1990) 195-202.
Zwirner, M., Bieglmayer, C., Klapdor, R., Kreienberg, R., Lüthgens, M.
An international proficiency study with the tumor marker CA 125.
Int. J. Biol. Markers 5 (1990) 55-60.
Franken, N., Jaworek, D.
Evaluierung eines neuen, automatisierten Enzym-Immunoassays zur Bestimmung von CA 15-3.
Extr. Diagn. 3 (1989) 18-26.
Bieglmayer, C., Klapdor, R., Kreienberg, R., Zwirner, M.:
Ergebnisse einer internationalen Ringstudie zur Qualitätssicherung der Bestimmung des tumorassoziierten Antigens CA 125. In: Tumor Diagnostik & Therapie 8 (1987) 150-155.
Zwirner, M.
Results of an international proficiency study on the quality of the tumor marker CA 153. (1987).
Fischbach, W., Mössner, J.:
Do size, histology, or cytology of colorectal adenomas and their removal influence serum CEA?
Dis. Colon Rectum 30 (1987) 595-599.
Dietel, M., Arps, H., Klapdor, R., Müller-Hagen, S., Sieck, M., Hoffmann, L.
Antigen detection by the monoclonal antibodies CA 19-9 und CA 125 in normal and tumor tissue and patients' sera. J. Cancer Res. Oncol. 111 (1986) 257-265.
Staab, H. J., Brümmendorf, T., Hornung, A., Anderer, F. A., Kieninger, G.:
The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastro-intestinal malignancies.
Klin. Wochenschr. 63 (1985) 106-115.
Klapdor, R., Klapdor, U., Bahlo, M., Dallek, M., Kremer, B., van Ackeren, H., Schreiber, H.W., Greten, H.:
CA 125 bei Karzinomen des Verdauungstraktes. Ein Vergleich mit CA 19-9 und CEA bei Karzinomen des Pankreas und Kolon.
Dtsch. med. Wschr. 109 (1984) 1949-1954